Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01890421 · ClinicalTrials.gov registry record · Phase 3
Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
A Phase 3 study of Coronary Artery Disease, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
- 20
- Study locations
NCT01890421 is a Phase 3 study of Coronary Artery Disease that has completed, run by Bayer. The registered enrollment target is 426 participants, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT01890421, a Phase 3 study of Coronary Artery Disease, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
- 20
- Study locations
Study Summary
Participants being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study. The duration for a participant in the study may range from 2 days to 4-6 weeks. One to four visits to the study doctor will be required. This study will investigate the diagnostic results of gadobutrol-enhanced Cardiac Magnetic Resonance Imaging (CMRI) images regarding the detection (sensitivity) and exclusion (specificity) of coronary artery disease utilizing a uniform image acquisition software. The CMR images will be tested either against the results from routine clinical Coronary Angiography (CA) or those from Computed Tomography Angiography (CTA), which is used as the standard of reference. The CA/CTA may have been performed up to 4 weeks prior to enrollment or be scheduled up to 4/6 weeks after the study. CMRI and CA/CTA images will be collected for an independent image review (blinded read).
Conditions Studied
Interventions
- DRUG Gadobutrol (Gadovist, Gadavist, BAY86-4875)
Study Locations (20)
Other
- - Marseille
- - Saint-Etienne
- - Berlin
- - Berlin
- - Berlin
- - Auckland
- - Incheon
- - Seoul
- - Seoul
- - Yangsan
Baden-Wurttemberg
- - Bad Krozingen
- - Stuttgart
- - Tübingen
North Rhine-Westphalia
- - Bonn
- - Essen
Minnesota
- - Minneapolis
Hesse
- - Darmstadt
Lower Saxony
- - Göttingen
Saxony
- - Leipzig
Canton Ticino
- - Lugano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2013-07-19 |
| Est. Completion | 2017-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01890421
The ClinicalTrials.gov registry entry for NCT01890421 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (67% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Gadobutrol (Gadovist, Gadavist, BAY86-4875) is the first listed.
NCT01890421 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Baden-Wurttemberg, North Rhine-Westphalia.
Frequently Asked Questions
What is clinical trial NCT01890421 about?
NCT01890421 is a clinical study titled "Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)". Participants being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study. The duration for a participant in the study may range from 2 days to 4-6 weeks. One to four visits to the study doctor will be required. Thi...
What is the current status of trial NCT01890421?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2013-07-19. Estimated completion is 2017-08-31.
What conditions does trial NCT01890421 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT01890421?
The interventions under investigation include: Gadobutrol (Gadovist, Gadavist, BAY86-4875) (DRUG).
Who is sponsoring clinical trial NCT01890421?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01890421 being conducted?
This trial has 20 study locations across Minnesota, Baden-Wurttemberg, Hesse, Lower Saxony, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
RECRUITING · Phase 3
-
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
RECRUITING · Phase 3
-
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
ACTIVE NOT RECRUITING · Phase 3
-
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.